Adjuvant checkpoint inhibitors improve survival in high-risk head and neck cancer

This meta-analysis pooled phase III trials of immune checkpoint inhibitors (ICIs) added to chemoradiotherapy after resection of high-risk locally advanced head and neck squamous cell carcinoma.

Adding an ICI improved disease-free survival (hazard ratio 0.75, 95% CI 0.65–0.87) and overall survival (hazard ratio 0.74, 95% CI 0.65–0.85) — roughly a quarter fewer recurrences and deaths. The benefit was larger where PD-L1 combined positive score was 1 or more (HR 0.66). Toxicity was substantial: 81% had any-grade adverse events, 43–45% grade 3 or worse, immune-related effects such as hypothyroidism were more common, and 12–18% discontinued treatment because of adverse events.

For the multidisciplinary head and neck team this supports integrating adjuvant immunotherapy for selected high-risk resected patients, especially PD-L1-positive disease, while being clear-eyed about immune toxicity. It strengthens the case for PD-L1 testing on resection specimens and for building irAE monitoring into follow-up.

• Disease-free survival HR 0.75 and overall survival HR 0.74 with adjuvant ICI
• Greater benefit with PD-L1 CPS ≥ 1 (HR 0.66) — test the resection specimen
• Grade 3+ adverse events in 43–45%; 12–18% discontinued for toxicity
• Build immune-related adverse event monitoring into survivorship follow-up

The statistics, in plain English

A hazard ratio of 0.74 for overall survival means treated patients had about 26% lower risk of death over follow-up; both intervals sit clearly below 1.0. The larger effect at PD-L1 CPS ≥ 1 (HR 0.66) means the biomarker identifies who benefits most, which is why it should guide selection rather than treating everyone.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.